RE: Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
作者信息
Mark Michael, von Moos Roger, Cathomas Richard, Stoffel Sandro, Gillessen Silke
机构信息
Department of Haematology/Oncology, Kantonsspital Graubünden, Chur, Switzerland.
Institute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland.
出版信息
J Natl Cancer Inst. 2022 Apr 11;114(4):635-636. doi: 10.1093/jnci/djab216.
Abstract
摘要
相似文献
1
RE: Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.关于：骨改良剂在转移性去势敏感性前列腺癌中的真实世界应用。
J Natl Cancer Inst. 2022 Apr 11;114(4):635-636. doi: 10.1093/jnci/djab216.
2
Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer.重新审视骨改良剂在转移性前列腺癌治疗中的作用。
Asia Pac J Clin Oncol. 2018 Nov;14 Suppl 5:13-15. doi: 10.1111/ajco.13061.
3
Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.使用骨扫描指数预测转移性激素敏感性前列腺癌男性患者出现去势抵抗性前列腺癌的时间
Urol Int. 2017;99(4):400-405. doi: 10.1159/000477131. Epub 2017 Jun 14.
4
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.反驳观点：在有症状的转移性去势抵抗性前列腺癌中，多西他赛和镭-223应首先使用哪一种？镭-223是骨转移为主的有症状转移性去势抵抗性前列腺癌的首选治疗方法。
Clin Adv Hematol Oncol. 2015 May;13(5):293-8.
5
Prostate-Specific Antigen Flare Phenomenon During Ra-Dichloride Treatment for Bone Metastatic Castration-Resistant Prostate Cancer: A Case Report.二氯化镭治疗骨转移性去势抵抗性前列腺癌期间的前列腺特异性抗原激增现象：一例报告
Clin Genitourin Cancer. 2016 Oct;14(5):e529-e533. doi: 10.1016/j.clgc.2016.04.014. Epub 2016 Apr 27.
6
Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone.抑制胰岛素样生长因子-1受体可增强去势对骨内前列腺癌生长大鼠模型的急性作用。
Clin Exp Metastasis. 2017 Apr;34(3-4):261-271. doi: 10.1007/s10585-017-9848-8. Epub 2017 Apr 26.
7
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.卡博替尼在骨转移性肾细胞癌和去势抵抗性前列腺癌中的生物学问题。
Future Oncol. 2018 Oct;14(25):2559-2564. doi: 10.2217/fon-2018-0158. Epub 2018 Aug 24.
8
Updated: Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience.
Tumori. 2019 Jun;105(3):271. doi: 10.1177/0300891619836496. Epub 2019 Mar 14.
9
Editorial Comment to Effect of upfront combination therapy on the overall survival of patients with metastatic castration-sensitive prostate cancer: A multicenter retrospective study.关于 upfront 联合治疗对转移性去势敏感性前列腺癌患者总生存影响的编者按：一项多中心回顾性研究
Int J Urol. 2022 May;29(5):478-479. doi: 10.1111/iju.14864. Epub 2022 Mar 16.
10
Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.利用治疗剂的潜力来保护前列腺癌患者的骨骼健康。
Prostate Cancer Prostatic Dis. 2018 Nov;21(4):461-472. doi: 10.1038/s41391-018-0060-y. Epub 2018 Jul 9.
引用本文的文献
1
Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare.医疗保险优势计划与传统医疗保险中低价值癌症治疗的使用情况
J Clin Oncol. 2025 Jul 10;43(20):2245-2254. doi: 10.1200/JCO-24-01907. Epub 2025 May 31.
2
Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects.实体瘤骨转移的骨改良药物治疗：一项针对意大利肿瘤学家的网络调查，旨在研究药物处方和预防副作用的实践模式。
Support Care Cancer. 2024 Mar 1;32(3):202. doi: 10.1007/s00520-024-08392-8.
3
Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study.制药行业的支付与非推荐及低价值癌症药物的供应：基于人群的队列研究。
BMJ. 2023 Oct 25;383:e075512. doi: 10.1136/bmj-2023-075512.
本文引用的文献
1
Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.转移性去势敏感性前列腺癌中骨修饰剂的真实世界应用。
J Natl Cancer Inst. 2022 Mar 8;114(3):419-426. doi: 10.1093/jnci/djab196.
2
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.瑞士应用骨靶向药物预防有骨转移的去势敏感前列腺癌患者骨骼相关事件的治疗模式和经济后果 - SAKK 95/16 前列腺研究。
Swiss Med Wkly. 2021 Mar 1;151:w20464. doi: 10.4414/smw.2021.20464.
3
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.唑来膦酸延长给药间隔与标准给药对骨转移患者骨骼事件的影响：一项随机临床试验
JAMA. 2017 Jan 3;317(1):48-58. doi: 10.1001/jama.2016.19425.
Zotero 插件